Roi Tschernichovsky1,2, Lior H Katz3, Estela Derazne1,2, Matan Ben-Zion Berliner1,2, Maya Simchoni4, Hagai Levine5, Lital Keinan-Boker6,7, Alexandra Benouaich-Amiel1, Andrew A Kanner2,8, Yosef Laviv2,8, Asaf Honig9, Elizabeth Dudnik1,2, Tali Siegal1, Jacob Mandel9, Gilad Twig2,10, Shlomit Yust-Katz1,2. 1. Neuro-Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Gastroenterology and Hepatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 4. Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. 5. Braun School of Public Health and Community Medicine, Hadassah University Hospital - Ein Kerem, Jerusalem, Israel. 6. Israel Center for Disease Control, Israel Ministry of Health, Ramat Gan, Israel. 7. School of Public Health, University of Haifa, Haifa, Israel. 8. Department of Neurosurgery, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 9. Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel. 10. Institute of Endocrinology, Sheba Medical Center, Tel HaShomer, Israel.
Abstract
BACKGROUND: Gliomas manifest in a variety of histological phenotypes with varying aggressiveness. The etiology of glioma remains largely unknown. Taller stature in adulthood has been linked with glioma risk. The aim of this study was to discern whether this association can be detected in adolescence. METHODS: The cohort included 2 223 168 adolescents between the ages of 16 and 19 years. Anthropometric measurements were collected at baseline. Incident cases of glioma were extracted from the Israel National Cancer Registry over a follow-up period spanning 47 635 745 person-years. Cox proportional hazard models were used to estimate the hazard ratio (HR) for glioma and glioma subtypes according to height, body mass index (BMI), and sex. RESULTS: A total of 1195 patients were diagnosed with glioma during the study period. Mean (SD) age at diagnosis was 38.1 (11.7) years. Taller adolescent height (per 10-cm increase) was positively associated with the risk for glioma of any type (HR: 1.15; P = .002). The association was retained in subgroup analyses for low-grade glioma (HR: 1.17; P = .031), high-grade glioma (HR: 1.15; P = .025), oligodendroglioma (HR: 1.31; P = .015), astrocytoma (HR: 1.12; P = .049), and a category of presumed IDH-mutated glioma (HR: 1.17; P = .013). There was a trend toward a positive association between height and glioblastoma, however this had borderline statistical significance (HR: 1.15; P = .07). After stratification of the cohort by sex, height remained a risk factor for men but not for women. CONCLUSIONS: The previously established association between taller stature in adulthood and glioma risk can be traced back to adolescence. The magnitude of association differs by glioma subtype.
BACKGROUND: Gliomas manifest in a variety of histological phenotypes with varying aggressiveness. The etiology of glioma remains largely unknown. Taller stature in adulthood has been linked with glioma risk. The aim of this study was to discern whether this association can be detected in adolescence. METHODS: The cohort included 2 223 168 adolescents between the ages of 16 and 19 years. Anthropometric measurements were collected at baseline. Incident cases of glioma were extracted from the Israel National Cancer Registry over a follow-up period spanning 47 635 745 person-years. Cox proportional hazard models were used to estimate the hazard ratio (HR) for glioma and glioma subtypes according to height, body mass index (BMI), and sex. RESULTS: A total of 1195 patients were diagnosed with glioma during the study period. Mean (SD) age at diagnosis was 38.1 (11.7) years. Taller adolescent height (per 10-cm increase) was positively associated with the risk for glioma of any type (HR: 1.15; P = .002). The association was retained in subgroup analyses for low-grade glioma (HR: 1.17; P = .031), high-grade glioma (HR: 1.15; P = .025), oligodendroglioma (HR: 1.31; P = .015), astrocytoma (HR: 1.12; P = .049), and a category of presumed IDH-mutated glioma (HR: 1.17; P = .013). There was a trend toward a positive association between height and glioblastoma, however this had borderline statistical significance (HR: 1.15; P = .07). After stratification of the cohort by sex, height remained a risk factor for men but not for women. CONCLUSIONS: The previously established association between taller stature in adulthood and glioma risk can be traced back to adolescence. The magnitude of association differs by glioma subtype.
Authors: S E Hankinson; W C Willett; G A Colditz; D J Hunter; D S Michaud; B Deroo; B Rosner; F E Speizer; M Pollak Journal: Lancet Date: 1998-05-09 Impact factor: 79.321
Authors: Rebecca B Little; Melissa H Madden; Reid C Thompson; Jeffrey J Olson; Renato V Larocca; Edward Pan; James E Browning; Kathleen M Egan; L Burton Nabors Journal: Cancer Causes Control Date: 2013-03-03 Impact factor: 2.506
Authors: Shlomit Yust-Katz; Aya Bar Oz; Estela Derazne; Lior H Katz; Hagai Levine; Lital Keinan-Boker; Alexandra Amiel; Andrew Kanner; Yosf Laviv; Asaf Honig; I Shelef; Tali Siegal; Gilad Twig; Jeremy Kark Journal: J Neurol Sci Date: 2019-11-02 Impact factor: 3.181
Authors: Melissa Z Braganza; Cari M Kitahara; Amy Berrington de González; Peter D Inskip; Kimberly J Johnson; Preetha Rajaraman Journal: Neuro Oncol Date: 2012-09-05 Impact factor: 12.300
Authors: Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins Journal: N Engl J Med Date: 2015-06-10 Impact factor: 176.079
Authors: J Sabatier; E Uro-Coste; I Pommepuy; F Labrousse; S Allart; M Trémoulet; M B Delisle; P Brousset Journal: Br J Cancer Date: 2005-02-28 Impact factor: 7.640